ArticleFrontiers in medicine2025
Detection of Gas6/AXL complex and its expression changes in patients with ST-segment elevation myocardial infarction.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- N-Glycosylation of AXL Receptor Tyrosine Kinase Regulates Its Stability, Phosphorylation, and Oncogenic Function.Molecular & cellular proteomics : MCP · 2026Article
- Prenatal Naproxen Reprograms Histopathological and Molecular Facets of the Sex-Based Lung Injury in Adult Offspring of Preeclamptic Rats.International journal of molecular sciences · 2026Article
- Reprogramming the tumor microenvironment with antibody against membrane-proximal AXL to overcome immune checkpoint blockade resistance.Signal transduction and targeted therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: It has been reported Gas6/AXL pathway participates in several diseases. However, due of the lack of specific antibody, the significance and change circulatory Gas6/AXL complex in related diseases remain unclear. Methods: The mice were immunized with human AXL protein which were expressed by L cells to obtain monoclonal antibodies (mAbs). The flow cytometry was used to monoclonal antibodies screening and binding region mapping. To prepare an AXL-Gas6 specific mAb coated ELISA plate, and test the level of AXL-Gas6 complex in human blood. Results and discussion: We successfully obtained an AXL monoclonal antibody only binding to Gas6/AXL complex. Using the antibody, we firstly found that AXL expressed on human pDCs had bind to Gas6. Not only applicated in flow cytometry, this novel antibody could also be used as capture antibody in ELISA. Depend on this antibody, we firstly discovered that sAXL Gas6 complex was significantly increased in patients with AMI. Compared to AXL detected by commercial kit, AXL-Gas6 complex we measured emerged as a more sensitive biomarker and risk factor for patients with ST-segment elevation myocardial infarction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.